Hip surgery recovery secrets sought in new study
NCT ID NCT07472400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 60 people aged 18 to 40 who are having hip arthroscopy for femoroacetabular impingement syndrome. Researchers measure strength, mobility, and function before surgery and at 3 and 6 months after. The goal is to find what helps patients recover best and to spot any lasting problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors design better rehab programs for people recovering from hip surgery.
- What could go wrong
- This is an observational study, not a treatment trial. It won't test a new drug or cure, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults aged 18-40 years will be recruited. The patient group will include individuals diagnosed with femoroacetabular impingement syndrome who are scheduled to undergo hip arthroscopy by specialized surgeons. A healthy control group without a history of hip pathology will be recruited from the local community matched as closely as possible to the patient group for demographic parameters.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects with femoroacetabular impingement syndrome, with corresponding clinical symptoms and signs, as well as validation by imaging * Subjects who have already consulted a surgeon specializing in hip arthroscopic surgery and whose surgery is planned to treat femoroacetabular impingement syndrome * Subjects aged between 18 and 40 Exclusion Criteria: * History of rheumatic disease, dysplasia or pediatric disease affecting the hip (Legg-Calvé; superior femoral epiphysiolysis) * Subject who has already undergone surgery on the hip joint * Subjects with a history of injury to the muscles involved in the assessments within the last year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Femoroacetabular impingement syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Blanc Gravier sports centers
RECRUITINGSart Tilman, Liège, 4000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body